Advancing Mechanistic Understanding of Microbiome Therapeutics Through Pharmacokinetics & Engraftment Analysis to Demonstrate Clinical Credibility

• Examining mechanism of action data from microbiome therapeutic programs to build evidence-based narratives that strengthen regulatory and pharma partnership credibility
• Leveraging pharmacokinetic and engraftment data from clinical trials to deepen process understanding and demonstrate reproducible therapeutic activity in target indications
• Applying mechanistic insights from donor-derived and defined consortium programs to inform next-generation microbiome therapeutic development strategies

Speakers:

Ken Blount

Senior Vice President, Head of Microbiome Clinical & Product Development

Ferring Pharmaceuticals